Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
Cappuccini F. et al, (2020), Journal for ImmunoTherapy of Cancer, 8, e000928 - e000928
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Cappuccini F. et al, (2017), Oncotarget, 8, 47474 - 47489
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer
Cappuccini F. et al, (2016), Cancer Immunology, Immunotherapy, 65, 701 - 713
The Human Vaccines Project: A roadmap for cancer vaccine development
Romero P. et al, (2016), Science Translational Medicine, 8
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
Harrop R. et al, (2008), Cancer Immunology, Immunotherapy, 57, 977 - 986
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses
Harrop R. et al, (2007), Clinical Cancer Research, 13, 4487 - 4494
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated
Harrop R. et al, (2006), Cancer Immunology, Immunotherapy, 55, 1081 - 1090
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial
Harrop R. et al, (2006), Clinical Cancer Research, 12, 3416 - 3424
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
Harrop R. et al, (2006), Clinical Cancer Research, 12, 3416 - 3424
Identification of a major histocompatibility complex class I‐restricted T‐cell epitope in the tumour‐associated antigen, 5T4
Redchenko I. et al, (2006), Immunology, 118, 50 - 57
Identification and functional validation of MHC Class I epitopes in the tumour-associated antigen 5T4
Shingler WH. et al, (2005), IMMUNOLOGY, 116, 34 - 34
Phase II studies of MVA expressing the tumour antigen 5T4 given with 5-FU based chemotherapies: safety, immunogenicity and clinical responses
Drury N. et al, (2005), IMMUNOLOGY, 116, 34 - 34
Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4 + T-Helper 1 Responses
Leen A. et al, (2001), Journal of Virology, 75, 8649 - 8659
Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells.
Redchenko IV. and Rickinson AB., (1999), Journal of virology, 73, 334 - 342
CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis
Wilson A., (1998), International Immunology, 10, 1149 - 1157
Human CD8 + T Cell Responses to EBV EBNA1: HLA Class I Presentation of the (Gly-Ala)–Containing Protein Requires Exogenous Processing
Blake N. et al, (1997), Immunity, 7, 791 - 802
Inhibitory effect of calf fetuin on the cytotoxic activity of LAK cell-derived factors and tumor necrosis factor
Chertov OY. et al, (1994), Immunology Letters, 42, 97 - 100
Contribution of membrane-associated cytotoxic proteins to cytolysis of L929 and K562 target cells mediated by LAK cells with different phenotypes
Saschenko LP. et al, (1994), Immunology Letters, 39, 243 - 247
Time-dependent changes of LAK cell phenotypes correlate with the secretion of different cytotoxic proteins
Sashchenko LP. et al, (1993), Immunology Letters, 37, 153 - 157